ABSTRACT

Intracerebral haemorrhage (ICH) is much less common than ischaemic stroke (15% versus 85% in most Western studies), but is associated with a significantly worse prognosis. ICH is much more common in Asian populations, probably reflecting higher rates of small vessel disease, hypertension and genetic factors. Overall, ICH mortality rates approach 50% and there has been little effective treatment to date, except for the overall benefit from stroke unit care. Surgery for supratentorial ICH was not shown to be beneficial in a large recent trial of over 1000 patients, although controversies remain. For example, it still has an important role in selected patients with cerebellar ICH. Medical therapies to reduce brain edema and intracranial pressure, including glycerol and mannitol, are not of proven value. It is accepted that corticosteroids should not be used in ICH and may worsen outcomes. The management of acute hypertension is controversial and guidelines are based on little direct evidence. (Critical Care and Resuscitation 2005; 7: 185-188)

Key words:

Intracerebral haemorrhage, medical management, recombinant activated factor VII, review

  Full article available here